NYSE:ABBVBiotechs
AbbVie (NYSE:ABBV) Expands Eye Care Portfolio with Ripple Therapeutics Collaboration, Boosts Growth Potential
AbbVie(NYSE:ABBV) is navigating a period of significant developments, including a robust 4% increase in operational sales and strategic acquisitions to bolster its pipeline. However, challenges such as declining profit margins and competitive pressures persist. In the discussion that follows, we will explore AbbVie's core strengths, critical weaknesses, growth opportunities, and key threats to provide a comprehensive overview of the company's current business situation.